As a leader in cell therapy development and clinical manufacturing, Leela will play a key role in advancing Aspect’s therapeutic pipeline
Vancouver, BC, Canada – June 17, 2025 – Aspect Biosystems, a biotechnology company pioneering the development of Bioprinted Tissue Therapeutics as a new category in regenerative medicine, today announced the appointment of Leela Paris as Senior Vice President of Technical Operations. Reporting directly to CEO Tamer Mohamed, Leela will lead all technical operations including process development, analytics, manufacturing, quality, and facilities operations.
“At Aspect, we’re focused on combining our cutting-edge science with operational and manufacturing excellence to advance our mission of developing functional cures for some of the most elusive diseases,” said Tamer Mohamed, Founder and CEO of Aspect Biosystems. “Leela brings outstanding experience in technical operations and scaling cell therapy manufacturing, and I am thrilled that she is joining us at basecamp in Vancouver. Her leadership will be instrumental as we expand our development and manufacturing capabilities and move into an exciting new phase of growth and clinical translation.”
Leela brings extensive experience in advancing cell therapies from early-stage research through to late-stage clinical development. At Vertex Pharmaceuticals, she held several leadership roles, including Vice President of Manufacturing and Process Engineering. In that role, she led process and analytical development, manufacturing, quality control, and was the functional CMC regulatory strategy lead for cell and combination products targeting type 1 diabetes—from research through to Phase 3. She also developed and executed manufacturing network strategies to support scale and global reach, played a key role in regulatory filings across North America and Europe, and built and managed a cross-functional team of over 600 across multiple global sites. Prior to Vertex, Leela served as Director of GMP Clinical Manufacturing at Semma Therapeutics, a regenerative medicine company focused on diabetes that was acquired by Vertex in 2019. She holds a PhD in Medicinal Chemistry and Molecular Pharmacology from Purdue University.
“I can't wait to contribute to Aspect's mission of pushing the boundaries of what's possible in biotechnology,” said Leela Paris, Senior Vice President of Technical Operations, Aspect Biosystems. “This is an incredible opportunity to be part of a team that's truly doing amazing and innovative science, with the ultimate goal of helping patients and improving lives.”
About Aspect Biosystems
Aspect Biosystems is a biotechnology company pioneering the development of Bioprinted Tissue Therapeutics to transform how we treat some of the most elusive diseases. Aspect’s Bioprinted Tissue Therapeutics are designed to replace, repair, or supplement biological function inside the body. Aspect is creating these next-generation cell therapies by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, computational design tools, therapeutic cells, and advanced biomaterials. Aspect is advancing a pipeline of Bioprinted Tissue Therapeutics across multiple disease areas in the endocrine and metabolic space including diabetes, obesity, rare endocrine disorders, and liver disease. Aspect's pipeline development strategy involves both proprietary programs as well as strategic partnerships, including a collaboration with Novo Nordisk focused on diabetes and obesity. For more information, please visit www.aspectbiosystems.com and follow on LinkedIn.
Contact
Natalie Korenic
Aspect Biosystems
media@aspectbiosystems.com